Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C

Leland J. Yee, KyungAh Im, Abdus S. Wahed, Teodorica Bugawan, Jia Li, Shannon L. Rhodes, Henry Erlich, Hugo R. Rosen, T. Jake Liang, Huiying Yang

Research output: Contribution to journalArticle

Abstract

The dynamics of the viral decline immediately after the start of therapy for chronic hepatitis C virus (HCV) infection may have prognostic potential for ultimate sustained virologic response. Considerable interindividual variability in the decline has been reported, including differences by race. The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in the immune response to viral infections. We examined whether carriage of specific human MHC alleles are associated with the rate of the early viral decline. Longitudinal viral level data (baseline and days 1, 2, 7, 14, and 28 of treatment), medium resolution MHC genotyping, and random coefficients models were used to examine associations between MHC class I and class II allele carriage and the dynamics of the viral decline in 180 African-Americans (AAs) and 194 Caucasian Americans (CAs) with genotype-1 HCV infection over the first 28 days of treatment with peginterferon α2a plus ribavirin. Baseline viral levels were similar by race, irrespective of allele carriage. However, the rate of change in the viral decline was associated with both allele and race. Among the four subgroups defined by race and specific allele, the fastest rates of decline were observed (in terms of estimated mean viral declines log10 IU/ml during the first four weeks) in CA noncarriers for A*03 (2.75; P = 0.018), in CA carriers for Cw*03 (2.99; P = 0.046), and in CA noncarriers for DQA1*04 (2.66; P = 0.018) or DQB1*0402 (2.65; P = 0.018). MHC alleles are associated with the viral decline during the first 28 days of peginterferon therapy.

Original languageEnglish (US)
Pages (from-to)615-621
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number2
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Major Histocompatibility Complex
Alleles
Virus Diseases
Hepacivirus
Therapeutics
Ribavirin
HLA Antigens
African Americans
Genotype
Genes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. / Yee, Leland J.; Im, KyungAh; Wahed, Abdus S.; Bugawan, Teodorica; Li, Jia; Rhodes, Shannon L.; Erlich, Henry; Rosen, Hugo R.; Liang, T. Jake; Yang, Huiying.

In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 2, 02.2009, p. 615-621.

Research output: Contribution to journalArticle

Yee, LJ, Im, K, Wahed, AS, Bugawan, T, Li, J, Rhodes, SL, Erlich, H, Rosen, HR, Liang, TJ & Yang, H 2009, 'Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C', Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 615-621. https://doi.org/10.1128/AAC.00947-08
Yee, Leland J. ; Im, KyungAh ; Wahed, Abdus S. ; Bugawan, Teodorica ; Li, Jia ; Rhodes, Shannon L. ; Erlich, Henry ; Rosen, Hugo R. ; Liang, T. Jake ; Yang, Huiying. / Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. In: Antimicrobial Agents and Chemotherapy. 2009 ; Vol. 53, No. 2. pp. 615-621.
@article{64b0c0935743443d9f9a680979eeddc7,
title = "Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C",
abstract = "The dynamics of the viral decline immediately after the start of therapy for chronic hepatitis C virus (HCV) infection may have prognostic potential for ultimate sustained virologic response. Considerable interindividual variability in the decline has been reported, including differences by race. The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in the immune response to viral infections. We examined whether carriage of specific human MHC alleles are associated with the rate of the early viral decline. Longitudinal viral level data (baseline and days 1, 2, 7, 14, and 28 of treatment), medium resolution MHC genotyping, and random coefficients models were used to examine associations between MHC class I and class II allele carriage and the dynamics of the viral decline in 180 African-Americans (AAs) and 194 Caucasian Americans (CAs) with genotype-1 HCV infection over the first 28 days of treatment with peginterferon α2a plus ribavirin. Baseline viral levels were similar by race, irrespective of allele carriage. However, the rate of change in the viral decline was associated with both allele and race. Among the four subgroups defined by race and specific allele, the fastest rates of decline were observed (in terms of estimated mean viral declines log10 IU/ml during the first four weeks) in CA noncarriers for A*03 (2.75; P = 0.018), in CA carriers for Cw*03 (2.99; P = 0.046), and in CA noncarriers for DQA1*04 (2.66; P = 0.018) or DQB1*0402 (2.65; P = 0.018). MHC alleles are associated with the viral decline during the first 28 days of peginterferon therapy.",
author = "Yee, {Leland J.} and KyungAh Im and Wahed, {Abdus S.} and Teodorica Bugawan and Jia Li and Rhodes, {Shannon L.} and Henry Erlich and Rosen, {Hugo R.} and Liang, {T. Jake} and Huiying Yang",
year = "2009",
month = "2",
doi = "10.1128/AAC.00947-08",
language = "English (US)",
volume = "53",
pages = "615--621",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C

AU - Yee, Leland J.

AU - Im, KyungAh

AU - Wahed, Abdus S.

AU - Bugawan, Teodorica

AU - Li, Jia

AU - Rhodes, Shannon L.

AU - Erlich, Henry

AU - Rosen, Hugo R.

AU - Liang, T. Jake

AU - Yang, Huiying

PY - 2009/2

Y1 - 2009/2

N2 - The dynamics of the viral decline immediately after the start of therapy for chronic hepatitis C virus (HCV) infection may have prognostic potential for ultimate sustained virologic response. Considerable interindividual variability in the decline has been reported, including differences by race. The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in the immune response to viral infections. We examined whether carriage of specific human MHC alleles are associated with the rate of the early viral decline. Longitudinal viral level data (baseline and days 1, 2, 7, 14, and 28 of treatment), medium resolution MHC genotyping, and random coefficients models were used to examine associations between MHC class I and class II allele carriage and the dynamics of the viral decline in 180 African-Americans (AAs) and 194 Caucasian Americans (CAs) with genotype-1 HCV infection over the first 28 days of treatment with peginterferon α2a plus ribavirin. Baseline viral levels were similar by race, irrespective of allele carriage. However, the rate of change in the viral decline was associated with both allele and race. Among the four subgroups defined by race and specific allele, the fastest rates of decline were observed (in terms of estimated mean viral declines log10 IU/ml during the first four weeks) in CA noncarriers for A*03 (2.75; P = 0.018), in CA carriers for Cw*03 (2.99; P = 0.046), and in CA noncarriers for DQA1*04 (2.66; P = 0.018) or DQB1*0402 (2.65; P = 0.018). MHC alleles are associated with the viral decline during the first 28 days of peginterferon therapy.

AB - The dynamics of the viral decline immediately after the start of therapy for chronic hepatitis C virus (HCV) infection may have prognostic potential for ultimate sustained virologic response. Considerable interindividual variability in the decline has been reported, including differences by race. The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in the immune response to viral infections. We examined whether carriage of specific human MHC alleles are associated with the rate of the early viral decline. Longitudinal viral level data (baseline and days 1, 2, 7, 14, and 28 of treatment), medium resolution MHC genotyping, and random coefficients models were used to examine associations between MHC class I and class II allele carriage and the dynamics of the viral decline in 180 African-Americans (AAs) and 194 Caucasian Americans (CAs) with genotype-1 HCV infection over the first 28 days of treatment with peginterferon α2a plus ribavirin. Baseline viral levels were similar by race, irrespective of allele carriage. However, the rate of change in the viral decline was associated with both allele and race. Among the four subgroups defined by race and specific allele, the fastest rates of decline were observed (in terms of estimated mean viral declines log10 IU/ml during the first four weeks) in CA noncarriers for A*03 (2.75; P = 0.018), in CA carriers for Cw*03 (2.99; P = 0.046), and in CA noncarriers for DQA1*04 (2.66; P = 0.018) or DQB1*0402 (2.65; P = 0.018). MHC alleles are associated with the viral decline during the first 28 days of peginterferon therapy.

UR - http://www.scopus.com/inward/record.url?scp=59749101989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59749101989&partnerID=8YFLogxK

U2 - 10.1128/AAC.00947-08

DO - 10.1128/AAC.00947-08

M3 - Article

C2 - 18852273

AN - SCOPUS:59749101989

VL - 53

SP - 615

EP - 621

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -